Novel osmotic pump tablet using core of drug-resin complexes for time-controlled delivery system.

A novel elementary osmotic pump tablet was developed. The system uses the core of drug-resin complexes (DRCs) loaded with propranolol hydrochloride (PNH) for time-controlled delivery. In traditional osmotic pump tablets (OPTs), the lag time was always minimized. However, in the DRCs osmotic pump tablet (DRCOPT), the lag time was increased to achieve the time-controlled delivery. The quantity of osmotic agent in the core and channeling agent in the coating solution as well as weight gain were confirmed to be essential for the release behavior. A spherical symmetric design was applied to the optimization of the DRCOPT. The optimal formulation mainly consisted of DRC 100 mg, polyethyleneoxide (N80) 182 mg, and NaCl 30 mg. The ratio of cellulose acetate (CA)/polyethylene glycol 4000 was 15:3 (w/w) in coating solution, and the weight gain was 8%. The release behavior of the optimal DRCOPT was evaluated in media with different pH, rotation speeds, and ionic strength. It was found to generate a 2-h lag time, to deliver PNH at a rate of zero order from 2 h to 14 h in the medium of NaCl 0.15 mol/l, and the cumulative release at 24 h was 94%. Drug relee was independent of pH and rotation speed, but was proportional to ionic strength. In summary, the lag time could be used in therapeutic regimens with the characteristics of chronotherapy because of the lag time and provides a new concept for the development of osmotic pumps.

A novel time-controlled release system based on drug-resin complexes and elementary osmotic pump.

A novel time-controlled system based on elementary osmotic pump tablet containing a drug-resin complexes (DRCs) core is presented. In the traditional osmotic pump tablets (OPTs), the lag time was always minimized. On the contrary, in the DRCs osmotic pump tablet (DRCOPT), the lag time was increased to achieve time-controlled delivery. The system led to a zero-order drug release after an initial lag time. Polyethylene oxide (PEO) N80 was used as suspension agent and NaCl was applied as ion-exchange, osmotic pressure (electrolyte supplementary) agent, respectively. To examine the mechanism of this system, drug release behaviors were investigated under conditions of various osmotic pressures. A new method of combination of conductivity and HPLC was applied to determine the different fractions of NaCl in producing osmotic pressure, ion-exchange and electrolyte supplement. The pharmacokinetic studies conducted in beagle dogs showed that a steadier and controlled drug release behavior was obtained compared with the traditional formulations. On the basis of prescription of the DRCOPT, a good in-vitro-in-vivo correlation (IVIVC, R(2)=0.9541) was achieved. In addition, a lag time of 4 h was observed in in vivo experiment, which indicated that the DRCOPT can be used in therapeutic regimens with the characteristics of chronotherapy.